TriSalus Life Sciences, Inc. (TLSI)

Kritische 8-K Meldungen

WARNUNG: Kritische 8-K-Meldung(en)
HOCH Abgang Schlüsselpersonen (07.04.2026)
HOCH Abgang Schlüsselpersonen (09.02.2026)

Datum	Meldung	Schwere	Filing	Auszug
07.04.2026	Item 5.02 — Abgang Schlüsselpersonen	HOCH	SEC	nt to Section 13(a) of the Exchange Act. o Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
09.02.2026	Item 5.02 — Abgang Schlüsselpersonen	HOCH	SEC	nt to Section 13(a) of the Exchange Act. o Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
01.10.2025	Item 5.02 — Abgang Schlüsselpersonen	HOCH	SEC	nt to Section 13(a) of the Exchange Act. o Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
29.08.2025	Item 5.02 — Abgang Schlüsselpersonen	HOCH	SEC	nt to Section 13(a) of the Exchange Act. o Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
23.04.2025	Item 5.02 — Abgang Schlüsselpersonen	HOCH	SEC	nt to Section 13(a) of the Exchange Act. o Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
17.04.2025	Item 5.02 — Abgang Schlüsselpersonen	HOCH	SEC	nt to Section 13(a) of the Exchange Act. o Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
25.02.2025	Item 5.02 — Abgang Schlüsselpersonen	HOCH	SEC	nt to Section 13(a) of the Exchange Act. o Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
31.01.2025	Item 5.02 — Abgang Schlüsselpersonen	HOCH	SEC	nt to Section 13(a) of the Exchange Act. o Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
01.11.2024	Item 5.02 — Abgang Schlüsselpersonen	HOCH	SEC	Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Directors;
07.05.2024	Item 5.02 — Abgang Schlüsselpersonen	HOCH	SEC	Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;
25.01.2024	Item 5.02 — Abgang Schlüsselpersonen	HOCH	SEC	Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Directors
16.08.2023	Item 5.02 — Abgang Schlüsselpersonen	HOCH	SEC	n Stock immediately following the Closing. Item 5.02. Departure of Directors or Certain Officers; Election of Director

Stammdaten

TriSalus Life Sciences, Inc., an immunotherapy company that develops and commercializes immunotherapies for the treatment of liver and pancreatic tumors. The company offers the TriNav Infusion System for hepatic arterial infusion of liver tumors; and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. It also develops SD-101, an investigational immunotherapeutic with pressure-enabled drug delivery technology for hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company is based in Westminster, Colorado.

Unternehmen & Branche

Name	TriSalus Life Sciences, Inc.
Ticker	TLSI
CIK	0001826667
Boerse	US
Sektor	Healthcare
Industrie	Medical - Devices
SIC	3841 · Surgical & Medical Instruments & Apparatus

Wertpapier & Kennzahlen

CUSIP	–
ISIN	–
Typ	Common Stock
Marktkapitalisierung	164,7 Mio. USD
Beta	0,54
Dividendenrendite	0,00 %

Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »

Finanzkennzahlen (SEC XBRL)

Periode	Filing	Umsatz	Nettoergebnis	EPS	Aktiva	Eigenkapital
2025-12-31	10-K	45,151,000	-39,227,000	-1.84	35,331,000	-33,861,000
2025-09-30	10-Q	11,566,000	-10,811,000	-0.96	36,463,000	-26,725,000
2025-06-30	10-Q	11,213,000	-8,288,000	-0.27	41,317,000	-19,423,000
2025-03-31	10-Q	9,167,000	-10,375,000	-0.39	28,625,000	-34,370,000
2024-12-31	10-K	29,431,000	-30,045,000	-1.31	23,971,000	-25,894,000
2024-09-30	10-Q	7,349,000	-2,399,000	-0.12	27,477,000	-20,434,000
2024-06-30	10-Q	7,364,000	-4,332,000	-0.21	32,431,000	-25,263,000
2024-03-31	10-K		-13,206,000	-0.60
2024-03-31	10-Q	6,457,000	-13,206,000	-0.60	17,889,000	-36,037,000
2023-12-31	10-K	18,511,000	-59,363,000	-6.77	24,598,000	-27,065,000
2023-09-30	10-Q	5,193,000	-1,425,000	-0.14	33,554,000	8,292,000
2023-06-30	10-Q	4,612,000	-13,985,000	-35.84	12,237,794	-198,419,000
2023-03-31	10-Q	2,984,000	-8,313,000	-0.57	20,520,212	-184,519,000
2022-12-31	10-K	12,398,000	-47,187,000	-161.55	21,995,000	-177,132,000
2022-09-30	10-Q	3,923,000	-8,093,000	-25.95	251,325,064	-153,925,000
2022-06-30	10-Q		-8,679,000		250,554,641	-145,958,000
2022-03-31	10-Q		-7,873,000		250,400,300	-137,354,000
2021-12-31	10-K		4,767,283		250,533,179	-129,605,000
2021-09-30	10-Q		1,864,740		250,761,751	-19,612,814
2021-06-30	10-Q		378,866		251,207,793	5,000,006

Fondsaktivität (Vorquartalsvergleich)

Keine Fondsdaten für dieses Unternehmen vorhanden.

Insider-Transaktionen (12 Monate)

Datum	Insider	Rolle	Typ	Stückzahl	Kurs	Wert (USD)	Δ
2026-03-17	Szela Mary T	Director, Officer, CEO and President	Open Market Sale	-15,944	3.85	-61,384.40	-71,9%
2026-03-16	Stevens Jennifer	Officer, Chief Regulatory Officer	Open Market Sale	-774	4.12	-3,188.88	-3,7%
2026-03-16	Cox Bryan F.	Officer, Chief of Research	Open Market Sale	-579	4.12	-2,385.48	-2,8%
2026-03-16	Marshak Richard	Officer, Chief Commercial Officer	Open Market Sale	-419	4.12	-1,726.28	-2,0%
2026-03-16	Devlin Jodi	Officer, Chief of Clinical Operations	Open Market Sale	-273	4.12	-1,124.76	-1,3%
2026-03-12	Marshak Richard	Officer, Chief Commercial Officer	Open Market Sale	-1,589	4.09	-6,499.01	-7,6%
2026-03-12	Devlin Jodi	Officer, Chief of Clinical Operations	Open Market Sale	-1,772	4.09	-7,247.48	-8,5%
2026-03-12	Cox Bryan F.	Officer, Chief of Research	Open Market Sale	-1,467	4.09	-6,000.03	-7,0%
2026-03-12	Stevens Jennifer	Officer, Chief Regulatory Officer	Open Market Sale	-1,552	4.09	-6,347.68	-7,4%
2026-03-11	Marshak Richard	Officer, Chief Commercial Officer	Open Market Sale	-1,449	4.13	-5,984.37	-7,0%
2026-03-11	Szela Mary T	Director, Officer, CEO and President	Open Market Sale	-4,358	4.13	-17,998.54	-21,1%
2026-03-11	Stevens Jennifer	Officer, Chief Regulatory Officer	Open Market Sale	-1,204	4.13	-4,972.52	-5,8%
2026-03-11	Cox Bryan F.	Officer, Chief of Research	Open Market Sale	-1,138	4.13	-4,699.94	-5,5%
2026-03-11	Devlin Jodi	Officer, Chief of Clinical Operations	Open Market Sale	-1,162	4.13	-4,799.06	-5,6%
2026-02-23	Stansky Michael P	Director	Open Market Purchase	117,198	4.10	480,511.80	+563,0%
2026-02-23	Valle William	Director	Open Market Purchase	30,487	4.10	124,996.70	+146,4%
2026-02-23	Szela Mary T	Director, Officer, CEO and President	Open Market Purchase	30,487	4.10	124,996.70	+146,4%
2026-02-23	Stansky Michael P	Director	Open Market Purchase	243,900	4.10	999,990.00	+1171,6%
2026-02-23	Gordon Gary B.	Director	Open Market Purchase	9,756	4.10	39,999.60	+46,9%
2026-02-23	Patience David	Officer, Chief Financial Officer	Open Market Purchase	3,657	4.10	14,993.70	+17,6%
2025-05-19	Devlin Jodi	Officer, Chief of Clinical Operations	Open Market Sale	-4,764	5.18	-24,677.52	-28,9%
2025-05-19	Marshak Richard	Officer, Chief Commercial Officer	Open Market Sale	-6,597	5.18	-34,172.46	-40,0%
2025-05-19	Stevens Jennifer	Officer, Chief Regulatory Officer	Open Market Sale	-8,704	5.18	-45,086.72	-52,8%
2025-05-19	Cox Bryan F.	Officer, Chief of Research	Open Market Sale	-4,764	5.18	-24,677.52	-28,9%

Top-Fondshalter

Keine Fondsdaten zu dieser Aktie vorhanden.